GlassScriptPhysician profile
Jacqueline W Green
NPI 1427219609
$6,554.94
in general payments reported to CMS, 2019-2025
55 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,908 · 2020: $491 · 2021: $331 · 2022: $626 · 2023: $925 · 2024: $1,176 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,198.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,246.25 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $551.55 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $448.94 | 2019-2021 | |
| Pfizer INC. | $394.00 | 2019-2025 | |
| Amgen INC. | $364.80 | 2019-2025 | Uplizna |
| Ucb, INC. | $333.00 | 2020-2024 | Rystiggo, Briviact |
| Teva Pharmaceuticals USA, INC. | $262.85 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Acadia Pharmaceuticals INC | $230.32 | 2019-2025 | Nuplazid |
| Biogen, INC. | $211.06 | 2019-2025 | Spinraza, Leqembi |
| Genentech USA, INC. | $181.08 | 2019-2025 | Evrysdi |
| Celgene Corporation | $137.46 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $137.12 | 2019-2024 | Amyvid, Kisunla |
| Allergan, INC. | $132.34 | 2019-2020 | |
| Genzyme Corporation | $127.49 | 2019-2021 | |
| Lundbeck LLC | $122.47 | 2019-2025 | Vyepti |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.